Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AGMB

AgomAb Therapeutics NV ADR

14.50

Aug 07 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology Belgium Small NASD

Aug 06, 4:11 PMAgomab Therapeutics confirms 2026 outlook, says €252 million cash post-IPO funds operations into first half of 2029

Peers: INCY KYMR BMRN CRNX RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: SBIO

Scroll to Statements

Index	-
Market Cap	706.73M
Enterprise Value	571.36M
Income	-
Sales	-
Book/sh	3.15
Cash/sh	2.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	62
IPO	Feb 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.60
P/C	5.16
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.49
Current Ratio	6.49
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.26
EPS next Q	-0.45
EPS this Y	98.92%
EPS next Y	-26.33%
EPS next 5Y	75.90%
EPS past 3/5Y	-102.05% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-16.16% -

Insider Own	25.59%
Insider Trans	0.00%
Inst Own	22.51%
Inst Trans	49.54%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	13.42%
SMA50	18.62%
SMA200	16.54%
Trades

Shs Outstand	48.74M
Shs Float	36.64M
Short Float	3.39%
Short Ratio	13.10
Short Interest	1.24M
52W High	17.82 -18.63%
52W Low	8.75 65.71%
Volatility	8.45% 8.38%
ATR (14)	1.14
RSI (14)	60.44
Beta	-
Rel Volume	0.00
Avg Volume	94.81K
Volume	0

Perf Week	12.67%
Perf Month	11.28%
Perf Quarter	26.97%
Perf Half Y	-
Perf YTD	-1.36%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	33.42
Prev Close	14.50
Price	14.50
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-26	Initiated	B. Riley Securities	Buy	$34
Jun-22-26	Initiated	H.C. Wainwright	Buy	$35
Mar-03-26	Initiated	Morgan Stanley	Overweight	$28
Mar-03-26	Initiated	Leerink Partners	Outperform	$36
Mar-03-26	Initiated	JP Morgan	Overweight	$32

Aug-06-26 04:01PM	Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook (GlobeNewswire) -5.73% +7.41%
Jun-23-26 04:05PM	Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire) +6.20%
May-27-26 05:00AM	Agomab Announces Results of Annual General Meeting (GlobeNewswire) +5.61%
May-14-26 07:30AM	Agomab to Participate in Upcoming Conferences (GlobeNewswire)
Apr-23-26 06:14PM	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook (GlobeNewswire)
07:00AM	Loading…
Mar-26-26 07:00AM	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire) -7.70%
Feb-09-26 04:05PM	Agomab Announces Closing of Initial Public Offering (GlobeNewswire) +6.55%
Feb-07-26 10:55AM	Agomab indicated to open at $15.50, IPO priced at $16 (TipRanks)
Feb-05-26 07:24PM	Agomab Announces Pricing of Initial Public Offering (GlobeNewswire)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Ph.D.Dr. Tim Knotnerus MSc

FounderMr. Paolo Michieli Ph.D.

Chief Financial OfficerMr. Pierre Kemula B.Sc.

Vice President of Investor RelationsSofie Van Gijsel

General CounselMs. Ellen Lefever

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGMB

AgomAb Therapeutics NV ADR

Upgrade your Finviz experience